Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

47.64 -0.34 (-0.70%)
Streaming Delayed Price Updated: 3:23 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
34 35 Next >
Hims & Hers Health’s (NYSE:HIMS) Q1: Beats On Revenue, Full-Year Outlook Slightly Exceeds Expectations
Telehealth company Hims & Hers Health (NYSE:HIMS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 111% year on year to $586 million. Revenue guidance for the full... 
Via StockStory
Hims & Hers Health Q1 Earnings: Revenue Jumps 111%, Subscribers Up 38%, Q2 Guidance Falls Short Of Estimates, Shares Slide
Hims & Hers Health reports first-quarter revenue of $586.01 million, beating estimates of $538.2 million, according to Benzinga. 
Via Benzinga
Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results
From Hims & Hers
Via Business Wire
Earnings Scheduled For May 5, 2025
Via Benzinga
ETFs Last Week: Tech-Fueled Rally Powers Gains During Trade Optimism
Wall Street rebounds from tariff losses, with S&P 500 recording second consecutive weekly gain. Top performers were tech giants and leveraged ETFs. 
Via Benzinga
Topics ETFs Stocks World Trade
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Hims & Hers Names New COO. Stock Rallies.
Hims stock rose Monday after the telehealth program named technology industry veteran Nader Kabbani as its new chief operating officer. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Hims & Hers Appoints Ex-Amazon Exec Ahead Of Q1 Results
Hims & Hers Health shares are trading marginally lower Monday morning. The company earlier appointed Nader Kabbani as its new Chief Operations Officer, ahead of Q1 results. 
Via Benzinga
Hims & Hers: The Next Amazon? Novo Nordisk Might Be Prime Delivery
Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to expand into other healthcare areas. 
Via Benzinga
Hims & Hers Appoints Amazon Veteran Nader Kabbani COO To Support Expansion
A nearly 20-year Amazon veteran, Nader Kabbani said he was drawn to Hims & Hers by its potential to expand access to fast, reliable, and high-quality care. 
Via Stocktwits
Topics Artificial Intelligence Economy Government
Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer
From Hims & Hers
Via Business Wire
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Hims & Hers Health Earnings: What To Look For From HIMS
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Why Is Novo Nordisk Stock Trading Higher On Friday?
Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease affecting patients with obesity. 
Via Benzinga
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access initiatives. 
Via Benzinga
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Hims & Hers Stock Soars on Novo Nordisk Collaboration
Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all. 
Via MarketBeat
Most active stocks in Tuesday's session
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume! 
Via Chartmill
Why Hims & Hers Health and LifeMD Are Skyrocketing Today
Via The Motley Fool
Topics Stocks
Hims & Hers Health (HIMS) Shares Skyrocket, What You Need To Know
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 34.9% in the pre-market session after Novo Nordisk announced plans to offer its weight loss drug Wegovy through the company's (Hims &... 
Via StockStory
Topics Economy Government World Trade
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
Via Benzinga
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Top movers in Tuesday's pre-market session
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators
Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers. 
Via Stocktwits
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
The companies will collaborate to improve access to weight-loss drugs in the U.S. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.